Neurana Pharmaceuticals, Inc. is a privately held biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, such as acute, painful muscle spasms of the back. In May 2018, Neurana completed a $60M Series A financing led by Sofinnova Ventures and included participation from New Leaf Venture Partners, H.I.G. BioHealth, and Longitude Capital.
The team at Neurana Pharmaceuticals is comprised of experienced biotech executives committed to bringing a novel therapy to patients suffering from muscle spasms
CATHERINE BRISSON – Regulatory Affairs
JIM GALLAGHER – CMC, Manufacturing
JOHNNA HANNAH – Corporate Development
SANAM ARA VAUGHAN – Clinical Operations
TOM YONKER – Project Management